Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 4/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.39 |
| ▸ | FEN1 | P39748 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9993146 | 0.89 | RAB9A (0.67) | RAB9ANPC1GSK3BL3MBTL1MAPT | |
| SCHEMBL2010768 | 0.85 | RAB9A (0.61) | RAB9ANPC1KMT2AKDM4EALDH1A1 | |
| SCHEMBL2010007 | 0.85 | ALDH1A1 (0.49) | RAB9ANPC1GSK3BL3MBTL1MAPT | |
| SCHEMBL15489237 | 0.84 | RAB9A (0.49) | RAB9ANPC1GSK3BMAPTKMT2A | |
| SCHEMBL12465723 | 0.81 | GSK3B (0.50) | RAB9ANPC1GSK3BMAPTKMT2A | |
| SCHEMBL2011684 | 0.79 | NPC1 (0.38) | RAB9ANPC1GSK3BL3MBTL1MAPT | |
| SCHEMBL12543647 | 0.79 | NPC1 (0.38) | RAB9ANPC1GSK3BL3MBTL1MAPT | |
| SCHEMBL5214600 | 0.79 | RAB9A (0.61) | RAB9ANPC1L3MBTL1MAPTKMT2A | |
| SCHEMBL6202998 | 0.76 | RAB9A (1.00) | RAB9ANPC1GSK3BL3MBTL1MAPT | |
| SCHEMBL5219339 | 0.75 | NPC1 (0.50) | RAB9ANPC1GSK3BMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477990-B1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-08-20 | — | — | EP | disclosed |
| US-8680096-B2 | Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators | SANOFI-AVENTIS (FR) | 2014-03-25 | — | — | US | disclosed |
| US-8618301-B2 | 5-phenylpyrazolopyridine derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-12-31 | — | — | US | disclosed |
| US-8546424-B2 | Acetylene derivatives of 5-phenyl-pyrazolopyridine, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| EP-2507238-B1 | DIPHENYL-PYRAZOLOPYRIDINE COMPOUNDS, THEIR PREPARATION AND THEIR APPLICATION AS MODULATORS OF THE NUCLEAR RECEPTOR NOT | SANOFI SA (FR) | 2013-07-31 | — | — | EP | disclosed |
| EP-2477988-B1 | Acetylenic derivatives of 5-phenyl-pyrazolopyridine, process for their preparation and therapeutic use thereof | SANOFI SA (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-01-24 | — | — | US | disclosed |
| US-20120270897-A1 | ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-10-25 | — | — | US | disclosed |
| EP-2507238-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-10-10 | — | — | EP | disclosed |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI (FR) | 2012-09-27 | — | — | US | disclosed |
| EP-2477988-A1 | ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| EP-2477990-A1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-07-25 | — | — | EP | disclosed |
| WO-2011067544-A1 | DIPHENYL-PYRAZOLOPYRDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | SANOFI-AVENTIS (FR) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011033230-A1 | 5-PHENYL PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270897-A1 | ACETYLENE DERIVATIVES OF 5-PHENYL-PYRAZOLOPYRIDINE, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAT1, KCNH1, PC | RAB9A 2004/4885NPC1 1445/4885GSK3B 4645/4885 |
| US-20120245164-A1 | DIPHENYL-PYRAZOLOPYRIDINE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS NUCLEAR RECEPTOR NOT MODULATORS | NR4A3, NCOR1, NR4A2 | RAB9A 3336/4885NPC1 867/4885GSK3B 4699/4885 |
| US-20130023554-A1 | 5-PHENYLPYRAZOLOPYRIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | CBR3, CBR1, OGFR | RAB9A 1236/4885NPC1 956/4885GSK3B 3881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.